About Affimed
Affimed is a therapeutic antibody company developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases based on its proprietary TandAb® technology platform.
TandAb® Technology
TandAbs® are tetravalent bispecific antibody formats that have two binding sites for each antigen. They bind to target molecules on the surface of, for example,tumor cells and can activate immune effector cells like cytotoxic T-cells or natural killer (NK) cells.
Tandab® RECRUIT
Product Pipeline
| Compound | Target | Indication | Discovery | Preclinical | Phase I | Phase II |
|---|---|---|---|---|---|---|
| blue = current development status - green = planned development | ||||||
| AFM13 | CD30xCD16 | Hodgkin’s Lymphoma | 100% completed | 100% completed | 100% completed end 2011 | 100% completed end 2012 |
| AFM11 | CD19xCD3 | Non-Hodgkin’s Lymphoma | 100% completed | 50% completed 100% end 2010 | 100% completed end 2012 | 50% end 2012 |
| AFM12 | CD19xCD16 | Non-Hodgkin’s Lymphoma | 100% completed | 50% completed 100% completed end 2012 | - | - |